

## Special Issue

# Advances in Targeted Therapy of Neuroblastoma

### Message from the Guest Editor

Neuroblastoma is the most common extracranial solid tumor of childhood. Over the past few decades, the advances in targeted therapy of neuroblastoma have greatly improved patient survival outcomes, such as ALK inhibitors, RAS-MAPK inhibitors, targeting MYCN through AURORA and BET inhibitors, epigenetic therapies, and GD2-based immunotherapy. However, many patients still develop relapsed and refractory disease. Recent progress in the developmental origin and phenotypic plasticity of neuroblastoma has provided new insights into the pathogenesis of neuroblastoma. This knowledge, along with the cutting-edge single-cell applications of next-generation sequencing technologies, will inform a further delineation of the molecular basis of neuroblastoma, as well as the development of novel biomarkers and therapies for precision medicine strategies.

### Guest Editor

Dr. Xing-Guo Li

1. Graduate Institute of Biomedical Sciences, China Medical University, Taichung 110122, Taiwan
2. Research Center for Cancer Biology, China Medical University, Taichung 110122, Taiwan
3. Institute of Biochemistry and Molecular Biology, College of Life Sciences, China Medical University, Taichung 110122, Taiwan

### Deadline for manuscript submissions

closed (30 June 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/176937](https://mdpi.com/si/176937)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).